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OBJECTIVE—Monocyte chemoattractant protein-1 (MCP-1), a
chemokine binding to the CC chemokine receptor 2 (CCR2) and
promoting monocyte inﬁltration, has been implicated in the
pathogenesis of diabetic nephropathy. To assess the potential
relevance of the MCP-1/CCR2 system in the pathogenesis of
diabetic proteinuria, we studied in vitro if MCP-1 binding to the
CCR2 receptor modulates nephrin expression in cultured podo-
cytes. Moreover, we investigated in vivo if glomerular CCR2
expression is altered in kidney biopsies from patients with
diabetic nephropathy and whether lack of MCP-1 affects protein-
uria and expression of nephrin in experimental diabetes.
RESEARCH DESIGN AND METHODS—Expression of neph-
rin was assessed in human podocytes exposed to rh-MCP-1 by
immunoﬂuorescence and real-time PCR. Glomerular CCR2 ex-
pression was studied in 10 kidney sections from patients with
overt nephropathy and eight control subjects by immunohisto-
chemistry. Both wild-type and MCP-1 knockout mice were made
diabetic with streptozotocin. Ten weeks after the onset of
diabetes, albuminuria and expression of nephrin, synaptopodin,
and zonula occludens-1 were examined by immunoﬂuorescence
and immunoblotting.
RESULTS—In human podocytes, MCP-1 binding to the CCR2
receptor induced a signiﬁcant reduction in nephrin both mRNA
and protein expression via a Rho-dependent mechanism. The
MCP-1 receptor, CCR2, was overexpressed in the glomerular
podocytes of patients with overt nephropathy. In experimental
diabetes, MCP-1 was overexpressed within the glomeruli and the
absence of MCP-1 reduced both albuminuria and downregulation
of nephrin and synaptopodin.
CONCLUSIONS—These ﬁndings suggest that the MCP-1/CCR2
system may be relevant in the pathogenesis of proteinuria in
diabetes. Diabetes 58:2109–2118, 2009
D
iabetic nephropathy is characterized by in-
creased glomerular permeability to proteins (1).
Recently, much attention has been paid to the
role of podocyte injury in glomerular diseases,
including diabetic nephropathy (2,3), but the precise mo-
lecular mechanisms underlying the development of dia-
betic proteinuria remain unclear.
The slit diaphragm, a junction connecting foot pro-
cesses of neighboring podocytes, represents the major
restriction site to protein ﬁltration (4). Mutations of the
gene encoding for nephrin, a key component of the slit
diaphragm, are responsible for the congenital nephrotic
syndrome of the Finnish type (5). Furthermore, a link
between a reduction in nephrin expression and proteinuria
has been also reported in acquired proteinuric conditions,
including diabetic nephropathy (6–8), and studies in pa-
tients with incipient diabetic nephropathy have demon-
strated that nephrin downregulation occurs in an early
stage of the disease (9).
A number of factors, including high glucose, advanced
glycation end products, and hypertension play a role in the
pathogenesis of diabetic nephropathy (10). In addition,
monocyte chemoattractant protein-1 (MCP-1), a potent
mononuclear cell chemoattractant, is overexpressed
within the glomeruli in experimental diabetes (11,12) and
has been recently implicated in both functional and struc-
tural abnormalities of the diabetic kidney (13).
MCP-1 binds to the cognate CC chemokine receptor 2
(CCR2), which is predominantly expressed on monocytes
(14), and MCP-1–driven monocyte accrual is considered
the predominant mechanism whereby MCP-1 contributes
to the glomerular damage. However, the CCR2 receptor
has also been shown both in vitro (15,16) and in vivo
(17–19) in other cell types besides monocytes, and we
have recently demonstrated that both mesangial cells and
glomerular podocytes express a functionally active CCR2
receptor (20–22).
To assess the potential relevance of the MCP-1/CCR2
system in the pathogenesis of diabetic proteinuria we
studied in vitro if MCP-1 binding to the CCR2 receptor
modulates nephrin, expression in podocytes. Moreover,
we investigated in vivo if glomerular CCR2 expression is
altered in kidney biopsies from patients with diabetic
nephropathy and whether lack of MCP-1 affects protein-
uria and/or expression of nephrin in experimental
diabetes.
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All materials were purchased from Sigma-Aldrich (St. Louis, MO) and DAKO
(Glostrup, Denmark) unless otherwise stated.
In vitro study
Cell culture. Immortalized human podocytes were established, character-
ized, and cultured as previously described (7,22). Cells retained their pheno-
typic characteristics, including expression of nephrin, a speciﬁc marker of
differentiated podocytes, which was detectable in all cells. Podocyte expres-
sion of the CCR2 receptor was assessed by immunoblotting before the study,
as we have previously reported (20).
mRNA expression. Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Chatsworth, CA). Two micrograms of total RNA were reverse
transcribed into cDNA using avian myeloblastosis virus (AMV) reverse
transcriptase and poly-d(T) primers. Human nephrin, mouse nephrin, and
mouse MCP-1 mRNA expression were analyzed by real-time PCR using
predeveloped TaqMan reagents (Applied-Biosystems). Fluorescence for each
cycle was analyzed quantitatively and gene expression normalized relative to
the expression of the housekeeping genes glyceraldehyde-3-phosphate-dehy-
drogenase and hypoxanthine-phosphoribosyl transferase.
Immunoﬂuorescence. Cells, ﬁxed in 3.5% paraformaldehyde, were incu-
bated with either a guinea pig anti-nephrin or a rabbit anti-synaptopodin
(Progen Biotechnik, Heidelberg, Germany) antibody. After rinsing, ﬂuorescein
isothiocyanate (FITC)-conjugated secondary antibodies (SantaCruz Biotec-
nology, Santa Cruz, CA) were added. Fluorescent intensity was assessed on
six microscopic ﬁelds (100 cells) by digital analysis (Windows MicroImage,
version 3.4; CASTI Imaging) on images obtained using a low-light video
camera (Leica-DC100). The background ﬂuorescence was subtracted by
digital image analysis. The results, corrected for cell density, were expressed
as relative ﬂuorescence intensity (RFI) on a scale from 0 (ﬂuorescence of
background) to 255 (ﬂuorescence of standard ﬁlter).
Rho-kinase activity. Rho-kinase (ROCK) activity was assessed by determi-
nation of the phosphorylation state of myosin phosphatase target subunit 1
(MYPT1), a downstream target of ROCK (23). Cells were lysed in radioimmu-
noprecipitation assay buffer containing protease/phosphatase inhibitors. Total
protein concentration was determined using the DC-Protein Assay (Biorad).
Proteins were separated and electrotransferred and subsequently probed with
an anti–phospho-MBS/MYPT-Thr
853 antibody (Cyclex). After detection by
enhanced chemiluminescence, membranes were stripped and reprobed for
total MYPT using a rabbit anti-MYPT antibody (SantaCruz Biotechnology).
Human study
Human biopsies. The study was performed on 10 renal biopsies from
diabetic patients with overt nephropathy (persistent proteinuria 0.5g/24 h)
and eight control subjects obtained from normal kidney portions from
patients who underwent surgery for hypernephromas and did not have
proteinuria or glomerular abnormalities, as detected by light and immunoﬂu-
orescence microscopy. The study was approved by the ethical committee of
Genoa University, the procedures were in accordance with the Helsinki
Declaration, and informed consent was obtained from all subjects. Patient
biopsies presented classic histological features of diabetic nephropathy, and
those with other patterns of injury, such as vascular or interstitial lesions
without glomerular diabetic damage, were excluded. Control subjects were
selected to be comparable for age and sex, and individuals with diabetes
and/or hypertension were excluded. Hypertension was deﬁned as a blood
pressure 140/90 mmHg on at least three different occasions. Diabetic
retinopathy was assessed by direct funduscopic examination. Twenty-four-
hour urinary protein content was measured using the pyrogallol-red method in
three separate urine collections, plasma creatinine by the kinetic Jaffe ´
method, and A1C by ion-exchange liquid chromatography. Creatinine clear-
ance was estimated using the Cockcroft-Gault formula (24).
CCR2 protein expression and localization. Immunohistochemical stain-
ing was performed on 4-m parafﬁn sections of formalin-ﬁxed tissue. After
antigen retrieval in citrate buffer, endogenous peroxidase activity quenching
with 3% H2O2, and blocking with avidin-biotin and 3% BSA, sections were
incubated with a rabbit monoclonal anti-CCR2 antibody (Epitomics, Burlin-
game, CA) and the speciﬁc staining detected using the LSAB system-HRP.
Sections were visualized with an Olympus-Bx4I microscope. Normal spleen
sections served as positive control. Glomerular immunostaining was quanti-
ﬁed by a computer-aided image analysis system (Qwin; Leica). All glomeruli in
the sections were analyzed and results were expressed as percentage area of
positive staining per glomerulus. Evaluations were performed by two inves-
tigators in a blinded fashion.
Double immunoﬂuorescent staining was performed for CCR2 and synap-
topodin, a speciﬁc podocyte marker (25). After blocking with 3% BSA, sections
were incubated with a monoclonal anti-synaptopodin antibody (Progen Bio-
technik) for 18 h at 4°C, washed, then incubated with a RPE-conjugated goat
anti-mouse IgG-F(ab)2 fragment. After washing and further blocking in 3%
BSA, sections were incubated with the rabbit anti-CCR2 antibody for 18 h at
4°C, washed, incubated with a biotinylated swine anti-rabbit IgG for 1 h and
then with FITC-conjugated streptavidin.
Study in experimental diabetes
Animals. MCP-1–intact (MCP-1
/) C57BL6/J and MCP-1–deﬁcient (MCP-1
/)
B6.129S4-Ccl2tm1Rol/J mice from Jackson Laboratories (Bar Harbor, ME)
were maintained on a normal rodent diet under standard animal house
conditions. Diabetes (blood glucose 250 mg/dl) was induced in both
MCP-1
/ and MCP-1
/ mice, aged 8 weeks and weighing 22 g, by
intraperitoneal injections of streptozotocin (STZ)-citrate buffer (55 mg/kg
body weight per day) for 5 consecutive days (26). Mice sham injected with
sodium citrate buffer were used as controls. Groups of MCP-1
/ (n  6) and
MCP-1
/ (n  5) diabetic mice with equivalent blood glucose levels and
control nondiabetic MCP-1
/ (n  9) and MCP-1
/ mice (n  4) were
studied in parallel. Blood glucose obtained via saphenous vein sampling
between 12:00 P.M. and 1:00 P.M. on alert 4-h–fasted animals was measured
using a glucometer (Glucocard G meter; Menarini Diagnostics). Before being
killed, mice were placed in individual metabolic cages for a period of 18 h and
urinary albumin concentration measured by a mouse albumin enzyme-linked
immunosorbent assay kit (Bethyl Laboratories, Montgomery, TX). After 10
weeks of diabetes, mice were killed under anesthesia by exsanguination via
cardiac puncture. The kidneys were rapidly dissected out and weighed. The
right kidney was frozen in liquid nitrogen and then stored at 80°C for mRNA
analysis. The left kidney was ﬁxed in 10% PBS-formalin at room temperature
then parafﬁn embedded for light microscopy. Glycated hemoglobin was
measured in whole-blood samples obtained via cardiac puncture at the time of
death by quantitative immunoturbidimetric latex determination (Sentinel
Diagnostic, Milan, Italy).
Glomerular isolation. Glomeruli were isolated immediately after mice were
killed, using the Dynabeads method from Takemoto et al. (27). Brieﬂy,
anesthetized mice were perfused with 8  10
7 surface-inactivated Dynabeads
(Invitrogen). The kidneys, removed and minced, were digested in a collage-
nase A solution containing 100 units/ml DNase I (Roche Diagnostics, Milan,
Italy), then passed twice through a cell strainer. The cell suspension was
collected by centrifugation, then glomeruli containing Dynabeads were gath-
ered by the magnetic particle concentrator and washed. The procedure of
isolation and washing was repeated (6–8 times) until no tubular contami-
nation was found as assessed under light microscopy.
Nephrin, synaptopodin, and zonula occludens-1 protein expression.
After antigen retrieval and blocking 4-m kidney parafﬁn sections were
incubated with primary guinea pig anti-nephrin, or monoclonal anti-synap-
topodin (Progen Biotechnik), or rabbit anti-zonula occludens (ZO)-1 antibodies
(Zymed Laboratories), followed by incubation with secondary FITC-conju-
gated antibodies against guinea pig IgG, rabbit IgG, or mouse IgG-F(ab)2
fragment. After counterstaining with DAPI, sections were digitized and
quantitated as described above. On average, 20 randomly selected hilar
glomerular tuft cross-sections were assessed per mouse. Results were calcu-
lated as percentage positively stained tissue within the glomerular tuft.
Fluorescence color images were also obtained as TIF ﬁles by a confocal
laser-scanning microscope LSM-510 (Carl Zeiss, Oberkochen, Germany).
Western blotting. Renal cortex specimens were homogenized in either
Laemmli buffer (nephrin, ZO-1) or Tris (20 mmol/l, 500 mmol/l NaCl, pH 7.5)
lysis buffer containing 0.5% 3-[(3-cholamidopropyl)-dimethylammonio]-1-pro-
panesulfonate, 5 mmol/l EDTA, and protease inhibitors (synaptopodin).
Proteins were separated by SDS-PAGE and electrotransferred to nitrocellu-
lose membranes. Following blocking in 5% nonfat milk in Tris-buffered saline,
membranes were incubated with primary antibodies against nephrin (Progen
Biotechnik), synaptopodin (Synaptic Systems), or ZO-1 (Zymed) overnight at
4°C. After washing, secondary anti-rabbit/mouse horseradish peroxidase–
conjugated antibodies were added for 1 h. Detection was performed by
enhanced chemiluminescence (Amersham) and band intensity quantiﬁed by
densitometry.
Electron microscopy. Renal cortex specimens were ﬁxed in 3% glutaralde-
hyde in cacodylate buffer for 2 h, postﬁxed in 1% osmium tetroxide for 1 h,
dehydrated in graded ethanol, washed in acetone, and embedded in Epon 812.
Ultrathin sections for ultrastructural examination were stained with uranyla-
cetate and lead citrate and examined with a transmission electron microscope
(JEM 100 CX-II; JEOL, Tokyo, Japan). Two to three animals per group were
used for the analysis.
Data presentation and statistical analysis. The number of independent
experiments, carried out in at least triplicate, is reported in the legend to
ﬁgures. Data, presented as means 	 SE, geometric mean (25–75% percentile),
or fold change over control, were analyzed by Student’s t test or ANOVA, as
appropriate. Newman-Keuls and Pearson tests were used for post hoc
comparisons and correlation analysis, respectively. P 
 0.05 was considered
signiﬁcant.
MCP-1/CCR2 SYSTEM IN DIABETIC NEPHROPATHY
2110 DIABETES, VOL. 58, SEPTEMBER 2009RESULTS
In vitro study
The CCR2 receptor is constitutively expressed by
cultured human podocytes. We have recently demon-
strated that human cultured podocytes express the CCR2
receptor at both mRNA and protein level by RT-PCR,
cytoﬂuorimetry, and immunocytochemistry (22). This was
further conﬁrmed in the podocytes used in this study by
Western blotting. Immunoblotting showed a band migrat-
ing at 42 kDa, corresponding to the reported molecular
weight of CCR2, and a band of identical molecular weight
was seen in protein extracts from THP-1, a monocyte cell
line used as positive control (Fig. 1).
Effect of rh-MCP-1 on nephrin mRNA expression. We
next tested whether exposure to rh-MCP-1 alters nephrin
mRNA expression in cultured podocytes. Analysis by
quantitative real-time PCR demonstrated that exposure to
rh-MCP-1 at a concentration of 10 ng/ml induced a signif-
icant reduction in nephrin mRNA levels after 2 h, with a
return to baseline by 4 h (Fig. 2A). Endotoxin contamina-
tion of the rh-MCP-1 preparation was excluded by the
Limulus test assay. Cell viability was comparable in podo-
cytes exposed to either rh-MCP-1 or vehicle as assessed by
Trypan Blue exclusion test (98 vs. 99%).
Effect of rh-MCP-1 on nephrin protein expression.
Podocytes were exposed to rh-MCP-1 10 ng/ml for 2, 4, 6,
12, and 24 h and to increasing rh-MCP-1 concentrations
(0.1, 1, 10, and 100 ng/ml) for 4 h, then nephrin expression
assessed by immunoﬂuorescence. Addition of rh-MCP-1
induced a signiﬁcant decrease over control in nephrin
protein expression after 2 h that was sustained up to 24 h
and peaked at 4–6 h (Fig. 2B, D, and E). In dose-response
experiments, we found that MCP-1 induced nephrin down-
regulation in a concentration-dependent manner with a
minimum effective concentration of 0.1 ng/ml and a max-
imal response at 10 ng/ml (Fig. 2C). On the contrary, as
shown in Fig. 3, addition of rh-MCP-1 did not alter synap-
topodin protein expression.
MCP-1 induced nephrin downregulation via a CCR2-
ROCK-dependent pathway. To test whether nephrin
downregulation was a speciﬁc effect of MCP-1 occurring
via the CCR2 receptor, experiments were repeated either
in the presence or in the absence of a highly speciﬁc
inhibitor of CCR2 signaling, RS102895 (RS 6 mol/l),
added 60 min before rh-MCP-1 (10 ng/ml). RS, a member of
the spiropiperidine family, interacts speciﬁcally with the
CCR2 binding domain and has no signiﬁcant inhibitory
activity on other chemokine receptors (28). RS completely
prevented MCP-1–induced downregulation of nephrin mRNA
at 2 h and of nephrin protein at 4 h (Fig. 2G and H).
Similarly, the addition of Y27632 (10 mol/l), a pyridine
derivative with a speciﬁc inhibitory activity on the ROCK
family of protein kinases (29), also abolished MCP-1–
induced nephrin mRNA and protein downregulation (Fig.
2G and H). Furthermore, podocyte exposure to MCP-1 (10
ng/ml) induced a rapid and transient increase in phospho-
MYPT1, a speciﬁc ROCK substrate (23), and the signiﬁcant
2.5-fold rise in phospho-MYPT1 levels observed at 10 min
was completely abolished by the ROCK inhibitor Y27632
(Fig. 2F). Taken together these results indicate that neph-
rin diminution in response to MCP-1 occurred via a
CCR2-ROCK–dependent pathway.
Human study
The CCR2 receptor is overexpressed by glomerular
podocytes in patients with diabetic nephropathy. To
assess the in vivo relevance of our ﬁndings and to exclude
that CCR2 receptor expression was solely related to in
vitro culture conditions, we studied glomerular CCR2
expression in renal sections from 10 type 2 diabetic
patients with overt diabetic nephropathy and 8 control
subjects. Clinical and laboratory characteristics of both
study patients and controls are showed in Table 1.
In normal renal cortex only few glomerular cells per
kidney biopsy, predominantly podocytes and mesangial
cells, stained positively for CCR2, as assessed by immu-
nohistochemistry (Fig. 4A and D). Speciﬁcity of the anti-
body binding was conﬁrmed by disappearance of the
signal when the antibody was preabsorbed with a 10-fold
excess of control peptide (Fig. 4C).
In patients with diabetic nephropathy, CCR2 protein
expression was greatly enhanced (Fig. 4B and E) and
semi-quantitative analysis showed that the percentage
positive area was ninefold greater than in the controls
(19.7 	 2.94 vs. 2.0 	 0.43, P 
 0.001). Furthermore, there
was a positive correlation between staining for CCR2 and
extent of proteinuria (P 
 0.001, r  0.89), whereas no
correlation was found with other clinical parameters, such
as age, diabetes duration, A1C, and creatinine clearance.
To clarify which glomerular cell type overexpressed
CCR2, double-labeling immunoﬂuorescence was per-
formed in patients with diabetic nephropathy using both
CCR2 and synaptopodin, a speciﬁc podocyte marker (25).
The CCR2 receptor was primarily expressed by glomerular
podocytes as CCR2 staining showed a comma-like pattern
along the glomerular capillary wall (Fig. 4B) and the
positive staining for synaptopodin (Fig. 4G) colocalized
with the CCR2 staining (Fig. 4H).
In vivo study
Clinical parameters. As shown in Table 2, after 10
weeks of diabetes intact and deﬁcient MCP-1 mice showed
a similar degree of glycemic control. A signiﬁcant decrease
in body weight and a signiﬁcant increase in kidney weight-
to-body weight ratio were observed in the diabetic mice,
while these parameters were similar in diabetic MCP-1
intact and deﬁcient mice. The induction of diabetes re-
sulted in a signiﬁcant increase in albuminuria in MCP-1
/
mice, which was signiﬁcantly reduced in mice lacking
MCP-1. On the contrary, albuminuria was comparable in
nondiabetic MCP-1
/ and MCP-1
/ mice.
Glomerular MCP-1 mRNA levels are enhanced in
experimental diabetes. There was a signiﬁcant sixfold
increase in glomerular MCP-1 mRNA levels in diabetic
mice as compared with controls as assessed by quantita-
tive real-time PCR (diabetic mice: 9.46 	 2.20; control
subjects: 1.49 	 0,49, P 
 0.05 diabetics vs. control
NC PC PODO
42 kDa
FIG. 1. The CCR2 receptor is expressed by human podocytes. CCR2
protein expression was studied in human cultured podocytes by immu-
noblotting as described in RESEARCH DESIGN AND METHODS. Total proteins
were separated by SDS gel electrophoresis, transferred to nitrocellu-
lose membranes, and probed for the CCR2 receptor by immunoblotting
using a rabbit anti-human CCR2 antibody. A representative immuno-
blot is shown of the speciﬁc band for CCR2 at 42 kDa. NC: negative
control obtained by omitting the primary antibody. PC: positive control
of total protein extracts from the monocyte cell line THP-1. PODO:
total protein extracts from human podocytes.
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able in the MCP-1
/ animals.
MCP-1 deﬁciency prevents both nephrin and synap-
topodin downregulation in diabetic mice. To evaluate
whether MCP-1 modulates the expression of slit-dia-
phragm–associated proteins in vivo, in the context of
diabetes, we assessed nephrin, synaptopodin, and ZO-1
glomerular expression by immunoﬂuorescence. After 10
weeks of diabetes, there was a signiﬁcant diminution in
both nephrin and synaptopodin expression, which was
signiﬁcantly blunted in MCP-1
/ diabetic mice (Fig. 5A–
D). By contrast, diabetes did not alter glomerular ZO-1
protein expression in either MCP-1
/ or MCP-1
/ mice
(Fig. 5E and F). These results were conﬁrmed by immu-
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FIG. 2. MCP-1 reduces nephrin mRNA and protein expression via a CCR2-Rho-dependent mechanism in cultured human podocytes. A: Nephrin
mRNA levels measured by real-time PCR in podocytes exposed to either vehicle or rh-MCP-1 (10 ng/ml) for 2 and 4 h. Results were corrected for
the expression of the housekeeping gene glyceraldehydes-3-phosphate dehydrogenase and expressed as percentage decrease as compared with
control subjects (n  3, *P < 0.01 rh-MCP-1 at 2 h vs. control subjects). B: Podocytes were exposed to rh-MCP-1 (10 ng/ml) for 2, 4, 6, 12, and
24 h and (C) to rh-MCP-1 (0.1–1 to 10–100 ng/ml) for 4 h. Nephrin expression, assessed by immunoﬂuorescence, was expressed as percentage
change in RFI as compared with control subjects (n  3* P < 0.01 rh-MCP-1 at 2, 12, and 24 h over control subjects [e]; †P < 0.001 rh-MCP-1 at
4 and 6 h over control subjects; ‡P < 0.05 rh-MCP-1 at 1 ng/ml over control subjects; §P < 0.001 rh-MCP-1 at 10 ng/ml over control subjects).
Representative immunoﬂuorescence images are shown in D (vehicle) and E (rh-MCP-1 at 10 ng/ml for 4 h). Magniﬁcation 400. F: Podocytes were
exposed to MCP-1 (10 ng/ml) for 0, 10, 30, 60, 120, and 180 min (upper panel) and 10 min in the absence and/or in the presence of Y27632 (Y27
10 mol/l), a speciﬁc ROCK inhibitor (lower panel). Both total and phosphorylayed MYPT1 were assessed by immunoblotting on total protein
extracts. Representative blottings are shown. G: Podocytes were exposed to rh-MCP-1 (10 ng/ml) in the presence and in the absence of RS102895
(RS 6 mol/l), a CCR2 receptor antagonist, and Y27632 (Y27 10 mol/l), a speciﬁc ROCK inhibitor, added 60 min before rh-MCP-1. After 2 h
incubation, nephrin mRNA levels were measured by real-time PCR, corrected for the expression of the housekeeping gene glyceraldehydes-3-
phosphate dehydrogenase, and expressed as percentage change over control (n  3, *P < 0.05 rh-MCP-1 vs. others). H: At 4 h, nephrin protein
expression was assessed by indirect immunoﬂuorescence using a low-light video camera and expressed as percentage change in RFI as compared
to control subjects (n  3; *P < 0.05 rh-MCP-1 vs. others).
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6). Furthermore, we found that the diabetes-induced re-
duction in nephrin mRNA levels was signiﬁcantly dimin-
ished in mice lacking MCP-1 (diabetic MCP-1
/: 66.44 	
7.25; diabetic MCP-1
/: 18.33 	 12.85, percentage reduc-
tion vs. control; P 
 0.01 diabetic MCP-1
/ vs. control; NS
diabetic MCP-1
/ vs. control).
Electron microscopy analysis. Electron microscopy
was performed to assess whether there were early signs of
podocyte damage in the diabetic animals that were pre-
vented by the absence of MCP-1. As shown in Fig. 7 the
normal arrangement of interdigitating foot processes was
maintained in all groups and podocyte foot processes
appeared tall and narrow in both diabetic MCP-1
/ and
MCP-1
/ mice, indicating that changes in podocyte mor-
phology were not yet present in this early phase of
experimental diabetes.
DISCUSSION
The MCP-1/CCR2 system has been implicated in the patho-
genesis of diabetic glomerular sclerosis (13,21,30,31). The
results, herein reported, showing 1) overexpression of
CCR2 in kidney biopsies from patients with diabetic
nephropathy, 2) overexpression of MCP-1 in the glomeruli
from diabetic animals, 3) prevention of both albuminuria
and nephrin downregulation in diabetic MCP-1 deﬁcient
mice, and 4) decreased nephrin expression in cultured
podocyte exposed to recombinant MCP-1, indicate that the
MCP-1/CCR2 system is also of relevance in the pathogen-
esis of the diabetic proteinuria.
MCP-1 binding to the CCR2 receptor induced a signiﬁ-
cant downregulation of both nephrin mRNA and protein
expression. The effect was seen at a MCP-1 dose as low as
0.1 ng/ml and reached a peak 57% decrease at 10 ng/ml.
This concentration is within the higher physiological range
as it is comparable with that measured in vitro in cultured
podocytes exposed to high glucose (32) and in vivo at sites
of inﬂammation (33). The magnitude of nephrin downregu-
lation was comparable to that previously reported in
podocytes exposed to glycated albumin (9), angiotensin II
(9), and oxidized LDL (34). Furthermore, nephrin down-
regulation has been shown to occur to a comparable
extent in proteinuric conditions in humans (35). The
prompt decrease in nephrin mRNA levels may be a result
of a rapid change in transcriptional activity (36). However,
posttranscriptional mechanisms may also be involved as a
AU-rich element, which is typical of genes under posttran-
scriptional regulation, is present in the 3 untranslated
region of the nephrin gene (37). The signiﬁcant reduction
in nephrin protein at later time points, despite the rapid
return of the mRNA levels to baseline, suggests that
additional mechanisms of nephrin protein reduction, such
as ubiquitination and shedding, may also take place.
MCP-1–induced cytotoxicity is an unlikely explanation as
podocytes exposed to MCP-1 were vital and MCP-1 in-
duces a small increase in cell proliferation in this cell type
(22).
MCP-1–induced nephrin downregulation occurred via a
CCR2-Rho-kinase–dependent mechanism as podocyte ex-
posure to MCP-1 enhanced ROCK activity and blockade of
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FIG. 3. MCP-1 effect on synaptopodin expression in cultured human
podocytes. Podocytes were exposed either to rh-MCP-1 (10 ng/ml) (A)
or vehicle (B) for 4 h, then synaptopodin expression assessed by
immunoﬂuorescence. Representative immunoﬂuorescence images are
shown (magniﬁcation 800). C: Results were expressed as percentage
change in RFI as compared with control subjects (n  3 *NS rh-MCP-1
vs. control subjects). (A high-quality digital representation of this
ﬁgure is available in the online issue.)
TABLE 1
Control subjects and patients with diabetic nephropathy: clinical
parameters
Type 2
diabetes
Control
subjects
n 10 8
Age (years) 58.2 	 2.4 65.4 	 6.3
Sex (male/female) 6/4 6/2
Diabetes duration (years) 12.5 	 2.5 —
A1C (%) 7.5 	 0.6 —
Creatinine (mg/dl) 2.0 	 0.4 1 	 0.1
Creatinine clearance (ml/min) 46 	 6.9 —
Proteinuria (g/24 h) 4.08 	 0.6 —
Retinopathy (%) 90 —
Hypertension (%) 100 0
Data are means 	 SE.
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downregulation. Similarly, in endothelial cells MCP-1–
induced loss of tight junction proteins is mediated by a
CCR2-Rho–dependent pathway (38). Interestingly, recent
in vivo studies have shown that ROCK inhibition amelio-
rates proteinuria in experimental models of both type 1
and 2 diabetes (39,40).
To assess whether these in vitro ﬁndings were relevant to
in vivo pathophysiological conditions, we also studied by
immunohistochemistry CCR2 expression in both normal
A                                   B C
E D
FH G
FIG. 4. CCR2 staining of human glomeruli from control subjects and patients with diabetic nephropathy. CCR2 protein expression was evaluated
in human glomeruli from control subjects (A and D) and diabetic patients with overt nephropathy (B and E) by immunohistochemistry as
described in RESEARCH DESIGN AND METHODS. C: Nonspeciﬁc staining was determined by preabsorbing the anti-CCR2 antibody with a 10-fold excess
of control peptide. F: Double immunoﬂuorescence for CCR2 (F) and (G) the podocyte marker synaptopodin performed on the diabetic glomeruli
showed colocalisation of the positive staining, as demonstrated by merging (H). Magniﬁcation 400 (80 D and E). Arrows and arrowhead
indicate podocytes and mesangial cells, respectively. (A high-quality digital representation of this ﬁgure is available in the online issue.)
TABLE 2
Characteristics of experimental animals
Nondiabetic
MCP-1
/
Diabetic
MCP-1
/
Nondiabetic
MCP-1
/
Diabetic
MCP-1
/
Animals (n) 964 5
Blood glucose levels (mg/dl) 69 	 3 329 	 23* 70 	 6 372 	 29*
GHb (%) 3.89 	 0.30 11.65 	 0.11* 3.80 	 0.24 11.82 	 0.17*
Body weight (g) 28.32 	 0.57 21.63 	 1.12* 26.70 	 0.31 21.94 	 0.48*
Kidney weight/body weight ratio 5.31 	 0.08 7.60 	 0.41* 5.76 	 0.17 7.94 	 0.33*
Urinary albumin (g/18 h) 13.80 (7.88–21.87) 55.69 (35.57–86.67)† 15.57 (9.04–27.70) 26.23 (20.6–35.83)
Data are expressed as means 	 SE or median (25–75% percentile). *P 
 0.001 diabetic vs. nondiabetic mice; †P 
 0.01 diabetic MCP-1
/
mice vs. nondiabetic mice and vs. diabetic MCP-1
/.
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FIG. 5. Glomerular staining for nephrin, synaptopodin, and ZO-1 in diabetic wild-type and MCP-1 knockout mice. Kidney parafﬁn sections from
both diabetic and nondiabetic MCP-1
/ and MCP-1
/ mice were stained for nephrin, synaptopodin, and ZO-1 by immunoﬂuorescence as
described in RESEARCH DESIGN AND METHODS. B, D, and F: Quantiﬁcation of glomerular staining for nephrin (*P < 0.01 diabetic MCP-1
/ vs.
nondiabetic MCP-1
/ mice; †P < 0.001 diabetic MCP-1
/ vs. diabetic MCP-1
/ mice), synaptopodin (*P < 0.01 diabetic MCP-1
/ vs. diabetic
MCP-1
/ mice; †P < 0.05 diabetic MCP-1
/ vs. nondiabetic MCP-1
/ mice), and ZO-1 (P  NS). A, C, and E: Representative ﬁgures of nephrin,
synaptopodin, and ZO-1 glomerular staining. Magniﬁcation 400. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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diabetes and overt diabetic nephropathy. In normal kidneys,
only a few glomerular cells stained positively for CCR2 in a
predominantly podocyte/mesangial cell distribution. How-
ever, in patients with diabetic nephropathy there was a
ninefold increase in glomerular CCR2 expression as com-
pared to controls and both pattern of staining and colocalization
with the podocyte marker synaptopodin strongly indicate that
CCR2 was primarily overexpressed by podocytes.
In the kidney, CCR2 expression by glomerular podo-
cytes has been previously reported in a mouse model of
Alport syndrome (41) and we have recently demonstrated
CCR2 in crescentic glomerulonephritis in humans (22).
This is, however, the ﬁrst report of CCR2 overexpression
by podocytes in human diabetic nephropathy. Although
we acknowledge that biopsies from type 1 microalbumin-
uric patients would have been a more appropriate match
for our in vivo study in early STZ-induced diabetes, these
biopsies are rarely performed for clinically indicated diag-
nostic purposes and their use in research is restricted by
ethical reasons. The underlying mechanism of CCR2 in-
duction in diabetic nephropathy remains elusive; however,
both high glucose and hemodynamic stretch are known to
downregulate the CCR2 receptor and it is, thus, unlikely a
direct role of these insults. The observation that CCR2
expression is enhanced in a variety of glomerulopathies
characterized by podocyte damage raises the hypothesis
that CCR2 is induced in response to podocyte injury.
To further test the hypothesis of a link between the
MCP-1/CCR2 system and enhanced glomerular permeabil-
ity in diabetic nephropathy, we studied diabetic MCP-1
knockout mice. The induction of diabetes by STZ in this
model has been previously established and we and others
have shown reduction in macrophage inﬁltration, overex-
pression of both ﬁbronectin and transforming growth
factor-1, and albuminuria in this model (13,21), although
speciﬁc assessment of a potential link between ameliora-
tion of albuminuria and preservation of podocyte struc-
tural proteins was not examined.
After 10 weeks of diabetes, albuminuria was signiﬁ-
cantly greater in diabetic than in control mice. This was
paralleled by a signiﬁcant reduction in both nephrin mRNA
and protein expression. In the diabetic MCP-1
/ mice,
these effects were signiﬁcantly suppressed, suggesting that
in experimental diabetes MCP-1 contributes to both neph-
rin downregulation and enhanced glomerular permeabil-
ity. In keeping with this hypothesis, we found that MCP-1
was overexpressed in the glomeruli isolated from the
diabetic animals. Blood glucose levels and glycated hemo-
globin were similar in diabetic MCP-1
/ and MCP-1
/
mice, consistent with the beneﬁcial effect of MCP-1 deﬁ-
ciency observed in these mice being independent of the
glycemic factor. Furthermore, there was no difference in
nephrin expression between nondiabetic MCP-1
/ and
MCP-1
/ mice, suggesting that the absence of MCP-1
speciﬁcally affects diabetes-induced nephrin expression
and does not play an important role in the absence of
hyperglycemia.
Synaptopodin, an actin-associated protein with prefer-
ential localization in podocyte foot processes (25), was
also downregulated in diabetic MCP
/ mice and rescued
in diabetic MCP-1
/ mice. On the contrary, no changes in
ZO-1 glomerular expression were observed in the diabetic
animals and our data, thus, do not conﬁrm a previous
report showing ZO-1 downregulation in both STZ-induced
diabetic rats and type 2 diabetic mice (42). Differences in
species/strain may explain this discrepancy.
Previous studies in diabetic mice have shown that
nephrin loss and proteinuria are paralleled by podocyte
foot process effacement, an early marker of podocyte
injury (43–46). However, in our study downregulation of
nephrin and synaptopodin were unlikely because of podo-
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FIG. 6. Nephrin, synaptopodin, and ZO-1 expression in the renal cortex
from diabetic wild-type and MCP-1 knockout mice. Nephrin (A), syn-
aptopodin (B), and ZO-1 (C) expression was studied in renal cortex
from both diabetic and nondiabetic MCP-1
/ and MCP-1
/ mice by
immunoblotting as described in RESEARCH DESIGN AND METHODS. Densi-
tometry analysis and representative immunoblots are shown. *P < 0.05
diabetic versus others.
MCP-1/CCR2 SYSTEM IN DIABETIC NEPHROPATHY
2116 DIABETES, VOL. 58, SEPTEMBER 2009cyte damage as no evidence of podocyte foot process
effacement was found at the ultrastructural level in the
diabetic animals. This may also suggest that podocyte
damage is not strictly required for the loss of nephrin and
the development of proteinuria. Consistently with this
view, proteinuria occurs, in nephrin knockout animals,
even in the absence of any defects in the podocyte foot
processes (47).
Strategies preventing glomerular macrophage inﬁltra-
tion have proven beneﬁcial in experimental diabetes
(48,49) and reduced glomerular recruitment of macro-
phages may also be implicated in the protective effects
observed in the diabetic MCP-1
/ mice. In particular, the
protective effect of MCP-1 deﬁciency on synaptopodin,
which was not affected in vitro in podocytes exposed to
MCP-1, may be explained by a macrophage-dependent
mechanism.
In conclusion, our ﬁndings may have important implica-
tions for diabetic nephropathy in humans. Proteinuria is a
characteristic feature of diabetic nephropathy and a key
determinant of progression (1). Nephrin is downregulated
in early diabetic nephropathy and this has been implicated
in the pathogenesis of the diabetic proteinuria (9). Our
data showing an effect of the MCP-1/CCR2 on both albu-
minuria and nephrin support the hypothesis of a patho-
genic role of this system in the development of the diabetic
proteinuria and makes it an attractive target for develop-
ing new strategies directed toward reducing proteinuria in
diabetic and other nephrotic conditions.
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